Scholarlink

Purpose <p>To determine if pupil size at baseline, on treatment, or change in pupil size while on atropine was associated with myopia progression.</p> Methods <p>This study utilized data from the ATOM2 study, a prospective, randomized, double-masked trial. 400 children were randomized to receive atropine 0.5%, 0.1%, or 0.01% daily in both eyes in a 2:2:1 ratio. Demographic data, as well as pupil size (PS) under photopic (300&#xa0;lx) and mesopic (4&#xa0;lx) conditions, axial length (AL), and spherical equivalent (SE) data at baseline and on follow-up, were collected.</p> Results <p>At baseline, the mean photopic and mesopic pupil size was 3.96+/-0.63&#xa0;mm and 4.48+/-0.66&#xa0;mm, respectively. Pupils on higher doses were more dilated, with eyes with smaller PS at baseline having smaller PS on treatment. Multivariate analysis suggested that changes in axial length (AL) and spherical equivalent (SE) were strongly associated with age and change in PS, while PS on treatment was also associated with change in AL after controlling for sex, race and atropine dose. Receiver operating characteristic analysis, however, suggested that change in PS was a poor predictor of treatment response (area under curve: 0.53–0.69), with sensitivity being better than specificity. So while a larger change in PS (e.g. <i>≥</i>2.5&#xa0;mm in 6.0-8.9year old children, or <i>≥</i>2&#xa0;mm in older children) was more likely to be associated with a better result; having a smaller PS change did not necessarily suggest a poor result.</p> Conclusions <p>A larger change in pupil size on treatment was associated with a better treatment response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between pupil size and response to atropine therapy in the Atropine Treatment of Myopia study (ATOM2)

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Daniel Peh,
  • Bryan Sim,
  • Hla Myint Htoon,
  • Deborah Tan,
  • Audrey Chia

摘要

Purpose

To determine if pupil size at baseline, on treatment, or change in pupil size while on atropine was associated with myopia progression.

Methods

This study utilized data from the ATOM2 study, a prospective, randomized, double-masked trial. 400 children were randomized to receive atropine 0.5%, 0.1%, or 0.01% daily in both eyes in a 2:2:1 ratio. Demographic data, as well as pupil size (PS) under photopic (300 lx) and mesopic (4 lx) conditions, axial length (AL), and spherical equivalent (SE) data at baseline and on follow-up, were collected.

Results

At baseline, the mean photopic and mesopic pupil size was 3.96+/-0.63 mm and 4.48+/-0.66 mm, respectively. Pupils on higher doses were more dilated, with eyes with smaller PS at baseline having smaller PS on treatment. Multivariate analysis suggested that changes in axial length (AL) and spherical equivalent (SE) were strongly associated with age and change in PS, while PS on treatment was also associated with change in AL after controlling for sex, race and atropine dose. Receiver operating characteristic analysis, however, suggested that change in PS was a poor predictor of treatment response (area under curve: 0.53–0.69), with sensitivity being better than specificity. So while a larger change in PS (e.g. ≥2.5 mm in 6.0-8.9year old children, or ≥2 mm in older children) was more likely to be associated with a better result; having a smaller PS change did not necessarily suggest a poor result.

Conclusions

A larger change in pupil size on treatment was associated with a better treatment response.